New Delhi — Inito has raised $29 million in Series B funding to support the development of a broader at-home hormone and health diagnostics platform. The round was led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures. According to the announcement, the new funding brings the company’s total equity investment to $45 million.
Founded with the goal of enabling quantitative hormone testing at home, Inito launched its fertility monitor in 2021. The company reports that the system has since analyzed more than 30 million hormone data points and is used to measure biomarkers including FSH, estrogen, LH, and PdG. Inito states that its AI models interpret these measurements to help users understand hormone patterns. After supporting tens of thousands of pregnancies, the company is now expanding beyond fertility diagnostics.
Co-founders Aayush Rai and Varun AV said the company aims to make clinical-grade hormone insights accessible within the home. They noted that conventional diagnostics rely on traditional antibodies produced through slow and variable processes. According to the company, advances in computational protein design allow machine-learning models to create synthetic antibodies with improved sensitivity and consistency, enabling new types of at-home tests.
Swati Murarka, Principal at Bertelsmann India Investments, said Inito’s work reflects the convergence of science, AI, and personal health. Fireside Ventures Co-founder and Partner Kannan Sitaram said the company has built consumer trust through its focus on scientific accuracy.
Inito plans to use the funding to accelerate development of diagnostics designed through computational methods, with the goal of expanding access to a wider range of at-home tests.
